AMC Stock Forecast, How High Could It Go in 2025 and Beyond?
AMC Entertainment (NYSE:AMC) has been rising lately after years of…
Sell
35
SBFM Quote, Financials, Valuation and Earnings
Last price:
$1.46
Seasonality move
:
15.62%
Day range:
$1.44 - $1.63
52-week range:
$1.17 - $9.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.07x
P/B ratio:
0.30x
Volume:
146.1K
Avg. volume:
111.2K
1-year change:
-75.76%
Market cap:
$6.7M
Revenue:
$34.9M
EPS (TTM):
-$4.20
Analysts' Opinion
-
Consensus RatingSunshine Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $140.00, Sunshine Biopharma has an estimated upside of 376.19% from its current price of $1.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $140.00 representing 100% downside risk from its current price of $1.47.
Fair Value
-
According to the consensus of 1 analyst, Sunshine Biopharma has 376.19% upside to fair value with a price target of $140.00 per share.
SBFM vs. S&P 500
-
Over the past 5 trading days, Sunshine Biopharma has underperformed the S&P 500 by -12.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sunshine Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sunshine Biopharma has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Sunshine Biopharma reported revenues of $8.9M.
Earnings Growth
-
Sunshine Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sunshine Biopharma reported earnings per share of -$0.44.
Enterprise value:
-1.4M
EV / Invested capital:
-0.06x
Price / LTM sales:
0.07x
EV / EBIT:
--
EV / Revenue:
-0.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$11M
Return On Assets:
-16.66%
Net Income Margin (TTM):
-13.88%
Return On Equity:
-21.04%
Return On Invested Capital:
-21.04%
Operating Margin:
-14.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $9.1M | $26.7M | $36.2M | $7.5M | $8.9M | |
| Gross Profit | $3.5M | $8.9M | $11M | $2.4M | $2.7M | |
| Operating Income | -$9.3M | -$4.3M | -$5.7M | -$1.4M | -$1.3M | |
| EBITDA | -$26.8M | -$3.4M | -$5.1M | -$1.2M | -$1.2M | |
| Diluted EPS | -$3,374.60 | -$152.60 | -$4.20 | -$2.00 | -$0.44 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.8M | $13.4M | $24.9M | $28.8M | $24.5M | |
| Total Assets | $1.9M | $13.4M | $27M | $31.9M | $29.2M | |
| Current Liabilities | $864.8K | $95.2K | $6.9M | $6.5M | $5.8M | |
| Total Liabilities | $2.9M | $95.2K | $7.6M | $7.1M | $6.5M | |
| Total Equity | -$1.1M | $13.3M | $19.4M | $24.8M | $22.7M | |
| Total Debt | $2.7M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.8M | -$10.1M | -$11.1M | -$3.2M | -$1.7M | |
| Cash From Investing | -$14.8M | -$1.2M | -$1.8M | -$668.7K | -$176K | |
| Cash From Financing | $26.5M | $9.4M | $4.2M | $5.4M | $338.1K | |
| Free Cash Flow | -$6M | -$11.4M | -$12.9M | -$3.9M | -$1.9M | |
SBFM
Sector
Market Cap
$6.7M
$32.6M
Price % of 52-Week High
15.71%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-75.76%
-37.62%
Beta (5-Year)
1.174
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.59
200-day SMA
Sell
Level
$2.39
Bollinger Bands (100)
Sell
Level
1.37 - 2.39
Chaikin Money Flow
Sell
Level
-75.4M
20-day SMA
Sell
Level
$1.51
Relative Strength Index (RSI14)
Sell
Level
47.19
ADX Line
Buy
Level
25.17
Williams %R
Neutral
Level
-78.0887
50-day SMA
Buy
Level
$1.42
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
113.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.1698)
Buy
CA Score
(Annual)
Level (0.4227)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.25)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Stock Forecast FAQ
In the current month, SBFM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBFM average analyst price target in the past 3 months is $140.00.
-
Where Will Sunshine Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sunshine Biopharma share price will rise to $140.00 per share over the next 12 months.
-
What Do Analysts Say About Sunshine Biopharma?
Analysts are divided on their view about Sunshine Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sunshine Biopharma is a Sell and believe this share price will drop from its current level to $140.00.
-
What Is Sunshine Biopharma's Price Target?
The price target for Sunshine Biopharma over the next 1-year time period is forecast to be $140.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBFM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sunshine Biopharma is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SBFM?
You can purchase shares of Sunshine Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sunshine Biopharma shares.
-
What Is The Sunshine Biopharma Share Price Today?
Sunshine Biopharma was last trading at $1.46 per share. This represents the most recent stock quote for Sunshine Biopharma. Yesterday, Sunshine Biopharma closed at $1.47 per share.
-
How To Buy Sunshine Biopharma Stock Online?
In order to purchase Sunshine Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Reddit Stock Be In 5 Years?
On a wet March morning last year, the famously orange…
Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
47
RGC alert for Jun 18
Regencell Bioscience Holdings [RGC] is down 20.77% over the past day.
Sell
20
ENPH alert for Jun 18
Enphase Energy [ENPH] is up 3.78% over the past day.
Sell
26
FSLR alert for Jun 18
First Solar [FSLR] is down 0.21% over the past day.
